Ascendis Pharma A/S (ASND) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET

Company Participants

Tim Lee - Senior Director, Investor Relations

Jan Mikkelsen - President & Chief Executive Officer

Scott Smith - Senior Vice President & Chief Financial Officer

Stina Singel - Head of Clinical Development Oncology

Birgitte Volck - Senior Vice President Head of Clinical Development & Medical Affairs Endocrinology Rare Diseases

Joe Kelly - Head of US Commercial Endocrinology

Conference Call Participants

Jess Fye - JPMorgan

Josh Schimmer - Evercore ISI

David Lebowitz - Citibank

Li Watsek - Cantor

Paul Choi - Goldman Sachs

Vikram Purohit - Morgan Stanley

Leland Gershell - Oppenheimer

Joseph Schwartz - SVB Securities

Andreas Argyrides - Wedbush Securities

Yaron Werber - Cowen

Operator

Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that, today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Tim Lee, Senior Director Investor Relations. Please go ahead.

Tim Lee

Thank you, operator, and thank you everyone for joining our Third Quarter 2022 Financial Results Conference Call. I'm Tim Lee, Senior Director of Investor Relations at Ascendis Pharma.

Joining me on the call today is Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Senior Vice President and Chief Financial Officer; Dr. Stina Singel, Head of Clinical Development Oncology; Dr. Birgitte Volck, Senior Vice President Head of Clinical Development and Medical Affairs Endocrinology Rare Diseases; and Joe Kelly, Head of US Commercial Endocrinology.

Before we begin, I would like to remind you that, this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to our US commercialization and continued development of SKYTROFA for the US market, the commercialization of TransCon hGH for the EU market, our progress on our pipeline candidates, and our expectations, with respect to their continued progress, statements regarding the expected timing of approval and launch of TransCon PTH in the US market next year, statements regarding our strategic plans, our goals regarding our clinical pipeline, including the timing of clinical results, statements regarding the US market approval of SKYTROFA, and our pipeline product candidates statements, regarding our planned regulatory filings, our expansion into new therapeutic areas, and statements regarding the ability to create a sustainable leading global biopharma company. These statements are based on information that is available to us today.